The effect of pre-operative pregabalin on postoperative pain and morphine consumption after open gynaecological surgery by Keong, Lim Wei
  
THE EFFECT OF PRE-OPERATIVE PREGABALIN ON 
POSTOPERATIVE PAIN AND MORPHINE CONSUMPTION AFTER 
OPEN GYNAECOLOGICAL SURGERY 
 
 
by 
DR LIM WEI KEONG 
 
 
Dissertation Submitted in Partial Fulfillment of the Requirements For The 
Degree Of Master Of Medicine 
(ANAESTHESIOLOGY) 
 
 
UNIVERSITI SAINS MALAYSIA 
MAY 2016
ii 
 
ACKNOWLEDGEMENTS 
 
I am thankful to God, whose guidance had led me to choose anaesthesia as my career and I 
am always grateful for that. 
 
I am forever indebted to my parents Mr. Lim Kee Eang  and Madam Chan Lay Ngoh 
whom no replacement can substitute their kindness and care, their enthusiasm and prayers, 
their patience and love in perpetuating and upholding virtues especially to their children. 
 
My heartfelt gratitude to my beloved wife, Dr Loh Sze Yee, whose endurance and patience 
has become my inner strength and motivation. 
 
My sincere appreciation to my mentor and supervisor, Prof. Dr Shamsul Kamalrujan 
Hassan and Prof. Dr Nik Abdullah Nik Mohamad, whose wisdom, knowledge and 
understanding are always beyond my grasp, yet they are ever ready to share and impart 
their insights and good judgments. I would also like to thank to Dr Wan Nor Arifin Wan 
Mansor from Department of Biostatistics, for providing the help and guidance in data 
analysis and interpretation.  
 
Lastly, to all my colleagues, friends and supporting staff who have helped me directly or 
indirectly in this study, I express my deepest gratitude. 
 
 
 
iii 
 
TABLE OF CONTENTS 
 
TITLE 
ACKNOWLEDGEMENTS  
i 
ii 
TABLE OF CONTENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES 
LIST OF ABBREVIATIONS 
viii 
x 
ABSTRAK  
ABSTRACT  
xii 
xiv 
CHAPTER 1:   INTRODUCTION  
1.1 Introduction                                                                               1           
1.2  Problem Statement                                                                   4 
1.3 Justification of The Study                                                         4 
1.4 Objective of The Study                                                             5 
                       1.4.1  General Objective 
                                 1.4.2  Specific Objective 
1.5 Study Hypothesis                                                                      6                                                                                                                                                                                                                                   
 
iv 
 
CHAPTER 2: LITERATURE REVIEW 
 2.1 Physiology of Acute Pain                                                      7
 2.2  Development of Chronic Post Surgical Pain                                         9 
 2.3  Concepts in Peri-Operative Pain Management                                    13 
 2.4  Patient Controlled Analgesia                                                              16 
            2.5       Pain Assessment Tools                                                                        18 
                        2.5.1     Unidimentional Scale 
                                    2.5.1.1     Numerical Rating Scale                                          20 
                                    2.5.1.2     Visual Analog Scale                                                20 
                                    2.5.1.3      Verbal Rating Scale                                                21 
                        2.5.2     Multidimentional Scale                                                           22 
                                       
2.6 Pregabalin                                                                                        
              2.6.1    Introduction                                                                                       23                                                                            
              2.6.2    Antinociceptive Mechanism of Action                                             24       
              2.6.3    Pharmacokinetics                                                                              25  
              2.6.4    Pregabalin versus Gabapentin                                                           27  
              2.6.5    Indication and Contraindication of Pregabalin                                  28 
              2.6.6    Preparation and Dosing of Pregabalin in Malaysia                           28          
              2.6.7    Perioperative Analgesia Dosing of Pregabalin                                  29 
              2.6.8    Perioperative Analgesia Dosing of Gabapentin                                 31    
 
 
 
 
 
 
v 
 
CHAPTER 3: METHODOLOGY 
 3.1 Study Design 
 3.2 Inclusion and Exclusion Criteria 
 3.3 Sample Size Calculation 
 3.4 Study Protocol 
 3.5 Measurements Tools for Data collection 
            3.6       Study Flow Chart 
            3.7       Statistical Analysis                                                                                  40 
 
 
32 
32 
34 
35 
38 
39 
CHAPTER 4: RESULTS  
 4.1  Demographic Data 
 4.2  Morphine Consumption and Pain Score 
                        4.2.1    Morphine Consumption 
                        4.2.2    Resting Pain Score 
                        4.2.3    Moving Pain Score 
 4.3  Side Effects 
                        4.3.1    Sedation 
                        4.3.2    Nausea 
             4.3.3    Vomiting 
                       4.3.4    Blurred Vision                                                                               57                                                                 
                        4.3.5    Respiratory Depression                                                                57 
 
 
41 
 
45 
47 
49 
 
51 
53 
55 
vi 
 
CHAPTER 5:  DISCUSSION 
 5.1 Pain Scores and Morphine Consumption 
 5.2  Side Effects 
             5.2.1    Post-Operative Nausea and Vomiting     
                        5.2.2    Other Side Effects 
                        5.2.3    Limitations of This Study  
                        5.2.4    Clinical Implications 
 
 
58 
 
61 
63 
64 
64 
CHAPTER 6:  SUMMARY AND CONCLUSION 65 
CHAPTER 7:  RECOMMENDATIONS FOR FUTURE STUDY 65 
 REFERENCES 66 
 APPENDICES 
 I Patient Information Sheet and Consent Form in Malay 
 II  Patient Information Sheet and Consent Form in English 
 III Data Collection Form 
 
73 
81 
88 
 
 
  
       
 
 
vii 
 
LIST OF TABLES 
 
Table4.1 Demographic data of patients                                                 42                                         
  
Table 4.2 Comparison of median cumulative morphine consumptions 
                  of both control and treatment groups                                     45 
Table 4.3 Postoperative resting pain scores between control and pregabalin   
groups                                                                                     47 
Table 4.4 Postoperative moving pain scores between control and 
pregabalin groups                                                                   49 
Table 4.5 Postoperative sedation scores between control and pregabalin 
groups                                                                                     51 
Table 4.6 Postoperative nausea scores between control and pregabalin 
groups                                                                                     53 
Table 4.7 Postoperative vomit scores between control and pregabalin 
groups                                                                                     55 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
 
Figure 2.1 Peripheral and central roles of prostaglandin and cyclo-oxygenase-2 
in pain   perception and sensitization                                              11 
Figure 2.2      The pain pathway and interventions that can modulate activity at      
each point                                                                                        14 
Figure 2.3 Numerical Rating Scale (NRS)                                                       20 
Figure 2.4       Visual Analog Scale (VAS)                                                             21 
Figure 2.5      Structure of Pregabalin                                                                    23 
Figure 3.1      Pregabalin 150mg capsule                                                              37 
Figure 3.2      Multivitamin capsule (used as placebo)                                         37 
Figure 4.1       Mean age of patients in control and treatment  
                       (Pregabalin) groups                                                                          43   
Figure 4.2 Race distribution between control and treatment 
                       (Pregabalin) groups                                                                          44 
Figure 4.3  Median cumulative morphine consumption score at 1, 4,  
                    and 24 hour, post-operation for control and treatment 
                    (Pregabalin) group                                                                               46 
Figure 4.4    Mean resting pain score at 0, 1, 4, and 24 hour, post-operation for    
control and treatment (Pregabalin) group                                            48 
ix 
 
Figure 4.5 Mean moving pain score at 0, 1, 4, and 24 hour, post-operation for 
control and treatment (Pregabalin) group                                        50 
Figure 4.6 Mean sedation score at 0, 1, 4, and 24 hour, post-operation for control 
and treatment (Pregabalin) group                                                     52 
Figure 4.7 Mean nausea score at 0, 1, 4, and 24 hour, post-operation for control 
and treatment (Pregabalin) group                                                     54 
Figure 4.8 Mean vomit score at 0, 1, 4, and 24 hour, post-operation for control 
and treatment (Pregabalin) group                                                     56 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF ABBREVIATIONS 
 
ASA   American Society of Anaesthesiologists 
APS   Acute Pain Service  
BP   Blood Pressure 
BPI   Brief Pain Inventory 
FLACC  Faces, Legs, Activity, Cry, Consolability 
GA   General Anaesthesia 
GAD   Generalised Anxiety Disorder 
HR   Heart Rate 
IV   Intravenous 
MEAC   Minimum Effective Analgesic Concentration 
MPQ   McGill Pain Questionnaires 
MTC   Minimum Toxic Concentration 
NRS   Numerical Rating Scale  
NSAIDS  Non steroidal Anti Inflammatory Drugs  
OT   Operation Theater 
PCA   Patient-Controlled-Analgesia 
xi 
 
PACU   Post Anesthesia Care Unit 
PONV   Post-Operative Nausea and Vomiting 
RASS   Richmond Agitation Sedation Scale 
SD   Standard Deviation 
SpO2   Oxygen Saturation 
VAS   Visual Analogue Scale 
VRS   Verbal Rating Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
ABSTRAK 
 
Tajuk: 
KESAN PREGABALIN SEBELUM PEMBEDAHAN PADA TAHAP KESAKITAN 
DAN PENGGUNAAAN MORFIN SELEPAS PEMBEDAHAN SAKIT PUAN 
 
Latar Belakang: 
Penggunaan pregabalin sebelum waktu pembedahan telah dibukti dapat mengurangkan 
tahap kesakitan dan penggunaan morfin di kalangan pesakit surgical yang tertentu. Kami 
mengkaji kesan pregabalin yang dibagi sebelum pembedahan terhadap tahap kesakitan 
selepas pembedahan di kalangan pesakit yang menjalani pembedahan sakit puan.  
 
Objektif: 
Penyelidikan ini bertujuan untuk menilai kesan Pregabalin 150mg yang diberi sebelum 
pembedahan kepada pengurangan dalam penggunaan ubat opioid dan pengurangan 
kesakitan selepas pembedahan sakit puan. 
 
Metodologi: 
60 pesakit yang menjalani pembedahan sakit puan yang memenuhi kriteria kemasukan 
telah direkrut di Hospital Universiti Sains Malaysia dan dibahagi secara rambang ke dalam 
dua kumpulan. Oral pregabalin 150mg 1 jam sebelum pembedahan diberi kepada 
kumpulan Pregabalin (n=30) manakala placebo diberi kepada kumpulan kawalan (n=30). 
Regimen pembiusan yang standard diberi kepada kedua-dua kumpulan dan dua kumpulan 
xiii 
 
tersebut diberi morfin intravena selepas pembedahan melalui alat analgesia kawalan 
pesakit. Markah kesakitan selepas pembedahan dalam keaddan rehat dan bergerak telah 
dicatat menggunakan skala analog visual pada 0, 1, 4, 24 jam selepas pembedahan. 
Penggunaan morfin juga dicatat pada jangka masa tersebut.   
 
Keputusan: 
Didapati tiada perbezaan ketara di antara markah kesakitan ketika rehat (p= 0.083), markah 
kesakitan semasa bergerak (p= 0.680) atau pengunaan morfin (p= 0.740) di antara 
kumpulan pregabalin dan kumpulan kawalan pada 24 jam selepas pembedahan.  
 
Kesimpulan: 
Penggunaan oral pregabalin 150mg satu jam sebelum pembedahan didapati tidak 
menunjukkan pengurangan dalam penggunaan ubat opioid dan pengurangan markah 
kesakitan selepas menjalani pembedahan sakit puan. 
 
Kata Kunci: 
Pregabalin, morfin, kesakitan selepas pembedahan, rasa loya selepas pembedahan, muntah 
selepas pembedahan, selepas laparotomy.   
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ABSTRACT 
Title:    
THE EFFECT OF PRE-OPERATIVE PREGABALIN ON POSTOPERATIVE PAIN 
AND MORPHINE CONSUMPTION AFTER OPEN GYNAECOLOGICAL SURGERY 
 
Introduction :  
Preoperative pregabalin has been shown to reduce postoperative pain scores and morphine 
consumption in certain surgical groups. We studied the effect of preoperative pregabalin 
on post operative pain relief among patients undergoing open gynaecological operation.  
 
Objective:  
This was a prospective, randomised, double blinded study on the efficacy of preoperative 
oral pregabalin 150mg in reducing postoperative morphine consumption and pain scores 
after undergoing open gynaecological operation.. 
 
Methodology :  
60 patients undergoing open gynaecological operation that fulfilled inclusion and 
exclusion criteria were recruited in Hospital Universiti Sains Malaysia and randomized 
into two groups. Oral pregabalin 150mg was given to the pregabalin group (n=30) one 
hour prior to operation while placebo was given to the control group (n=30). A 
standardized regime of general anaesthesia was given to both groups and  intravenous 
morphine was delivered via a patient controlled analgesia machine. Post operative pain 
scores at rest and movement were recorded using numeric rating scale at 0, 1, 4 and 24 
xv 
 
hours postoperatively. Total morphine usage was also recorded at those intervals. 
 
Results:  
There were no significant differences in resting pain scores (p= 0.083), moving pain score 
(p= 0.680) or morphine consumption (p= 0.740) at 24 hours postoperatively between 
pregabalin and control group.  
 
Conclusion :  
The use of 150mg oral pregabalin preoperatively given one hour prior to operation did not 
decrease post-operative pain score and morphine consumption for patients who underwent 
open gynaecological operation under general anaesthesia.  
 
Keywords :  
pregabalin, morphine, postoperative pain, postoperative nausea, postoperative 
vomiting, post laparotomy 
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CHAPTER 1:   INTRODUCTION  
 
1.1 INTRODUCTION 
 
Pain is a consistent and predominant complaint of most individuals following surgical 
interventions. Poorly controlled postoperative pain is a cause of much morbidity in the 
surgical patient. Postoperative pain not only increases physiological and psychological 
complications, it also causes the increase in number of follow up visits and patient 
dissatisfaction (Joshi and Ogunnaike, 2005).   This is a recognized fact and our recent 
campaigns and programs targeted at managing pain as a fifth vital sign proves that. 
However, effective control of postoperative pain is still a major challenge. It is thought to 
be inadequately treated in one half of all the surgical procedures (Agarwal et al., 2008). 
 
Recent studies have pointed out that peripheral and central neuronal sensitization play an 
important role in the development of hyperalgesia and allodynia at the postoperative site in 
the acute setting and if uncontrolled, may lead to subsequent persistent postoperative pain 
or chronic pain (Vadivelu et al., 2010). The initial intensity and duration of pain leads to 
both peripheral and central sensitizations that synergistically exacerbate pain perception 
(Voscopoulos and Lema, 2010). A review of predictive factors relating to chronic pain 
noted that acute postoperative pain and the number of doses of postoperative analgesics 
were the best predictors of persistent pain following surgery (Perkins and Kehlet, 2000). 
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This understanding had led to the use of antihyperalgesic drugs, pre-emptive analgesia and 
an NMDA receptor antagonists to combat postoperative pain (Dirks et al., 2002; Richmond 
et al., 1993). 
 
Pregabalin is a structural analogue of the inhibitory neurotransmitter g-aminobutyric acid, 
but it is not functionally related to it (Ben-Menachem, 2004). Like its predecessor, 
gabapentin, it binds to the α-2-δ subunit of voltage-gated calcium channels, reducing the 
release of several excitatory neurotransmitters and blocking the development of 
hyperalgesia and central sensitization (Shneker et al., 2005; Chizh et al., 2007). Pregabalin 
has anticonvulsant, anti-hyperalgesic, and anxiolytic properties similar to gabapentin, but it 
has a more favourable pharmacokinetic profile, including dose-independent absorption 
(Guay, 2005; Frampton et al., 2005). It is also several times more potent than gabapentin 
while producing fewer adverse effects (Ben- Menacham, 2004). 
 
In the US, Pregabalin is indicated for the treatment of neuropathic pain associated with 
diabetic peripheral neuropathy, spinal cord injury, postherpetic neuralgia, fibromyalgia, 
and as an adjunctive theraphy for adult patient with partial onset seizure. In the European 
Union, pregabalin is indicated for peripheral and central neuropathic pain, epilepsy, and 
generalized anxiety disorder (Agarwal et al., 2008). 
 
In view of these properties of pregabalin, multiple trials have been carried out on the use of 
this drug in the perioperative period with the objective of preventing central sensitization 
and thereby reducing postoperative pain. A systematic review of 11 trials in 2010 showed 
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that pregabalin effectively reduce postoperative opioids consumption and opioids related 
adverse effects after surgery (Zhang et al., 2011).     
 
According to Zhang et al. (2011), patients who were given pregabalin ranging from 
150mg- 600mg 1-2 hour preoperatively showed reduction in post-operative opioid 
consumption and visual analogue scale. The studies included in this systemic review 
showed that this opioid sparing effect of pregabalin stretched across a diverse range of 
surgeries (laparoscopic cholecystectomy, laparoscopic hysterectomy, laparoscopic sleeve 
gastrectomy, abdominal hysterectomy and total hip arthroplasty).  Specifically, studies 
have shown that pregabalin premedication effectively lowers postoperative pain score for 
laparoscopic cholecsyectomy (Agarwal et al., 2008), laparoscopic sleeve gastrectomy 
(Cabrera Schulmeyer et al., 2010) and abdominal hysterectomy (Ittichaikulthol et al., 
2009). However, many study has shown that 300mg-600mg of preoperative pregabalin 
causes more sedation than placebo group (Joleka et al., 2008; Mathiesenet al., 2008; Chang 
et al., 2009; Kim et al., 2010).   
 
None of these trials investigated the role of preoperative single dose administration of 
150mg pregabalin in attenuating postoperative pain and opioid consumption after open 
gynaecological operation. The present study was therefore designed to evaluate the role of 
preoperative single dose of pregabalin for attenuating postoperative pain and analgesic 
consumption in patients undergoing open gynaecological operation.  
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1.2  PROBLEM STATEMENT 
 
 The concept of multimodal analgesia was introduced more than a decade ago as a 
technique to improve analgesia and reduce the incidence of opioid-related adverse events. 
The introduction of Pregabalin into the Malaysian health care system in recent years has 
opened up another option for preemptive analgesia.  
 
 Currently the use of Pregabalin is not routinely practiced as preemptive analgesia in 
hospitals in Malaysia. Nevertheless, pregabalin has been shown to reduce postoperative 
pain score and opioid consumption in numerous types of operation.  
 
1.3  JUSTIFICATION OF THE STUDY 
This study was designed to determine the efficacy of preoperative oral pregabalin 150mg 
in reducing post operative pain score and morphine consumption after undergoing open 
gynaecological operation. 
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1.4 OBJECTIVE OF THE STUDY 
 
1.4.1  GENERAL OBJECTIVE  
The objective of this study is to measure the effects of oral pregabalin 150mg as compared 
to no pregabalin with regards to post operative pain relief when given preoperatively to 
patients undergoing open gynaecological operation. 
 
1.4.2 SPECIFIC OBJECTIVES 
1. To evaluate the opioid sparing effects of preoperative oral pregabalin 150mg 
quantified by a reduction in morphine consumption at 1 hour, 4 hours and 24 hours 
postoperatively. 
2. To compare postoperative pain scores between the two treatment groups (oral 
Pregabalin 150mg vs No Pregabalin) as measured using the numeric rating scale at 
0 hour, 1 hour, 4 hours and 24 hours postoperatively. 
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1.5 STUDY HYPOTHESIS 
 
Null Hypothesis: 
Single preoperative dose of pregabalin would not reduce postoperative morphine 
requirements and pain score after open gynaecological surgery. 
 
Alternative Hypothesis: 
Single preoperative dose of pregabalin would reduce postoperative morphine requirements 
and pain score after open gynaecological surgery. 
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CHAPTER 2:  LITERATURE REVIEW 
 
2.1 PHYSIOLOGY OF ACUTE PAIN 
 
Pain is defined by the International Association for the Study of Pain (IASP) as ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage (Merskey & Bogduk, 1994). 
 
Many neural processes occur before a person experiences the sensation of acute pain. 
Initially, primary afferent nociceptors are activated upon contact with noxious stimuli and 
change these stimuli into electrical signals in a process called transduction (Leon-Casasola, 
2007). 
 
Noxious stimuli are then transmitted from the primary afferent nociceptors and relayed to 
the thalamus followed by the cortex. This process of transmission is mainly done by 2 
types of nociceptive neurons which are A-delta fibers and C fibers (Leon-Casasola, 2007). 
 
A-delta fibers are 2-5 microns in diameter, myelinated and conduct at the velocity of 6-30 
meters per second. These fibers are activated by high intensity mechanical stimulation- 
these are called high threshold mechanoreceptors. Some of them are responded to thermal 
stimuli and are therefore called mechano-thermal receptors (Leon-Casasola, 2007). 
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C-fibers are less than 2 microns in diameter, unmyelinated and conduct at velocity of 0.5-2 
meters per second. These fibers transmit a variety of noxious stimuli which include 
mechanical, thermal and chemical stimuli and therefore are called C- polymodal 
nociceptors (Leon-Casasola, 2007). 
 
At the spinal cord level, these fibers travel along the dorsal root and enter the dorsal horn 
laterally. These small myelinated fibers mainly terminated in the superficial dorsal horn 
(lamina I) and lamina V. Unmyelinated fibers terminate in lamina II. Some of these fibers 
ascend and descend in Lissauer’s tract before terminating in the spinal cord. The noxious 
stimuli then transmitted to the cortex through spinothalamic tract (Leon-Casasola, 2007). 
 
The noxious stimuli is also processed and is termed modulation. This mainly happen in 
spinal cord. Descending neural tract can selectively inhibit or facilitate transmission of 
signals received at the dorsal horn of the spinal cord. In the dorsal horn itself, nociceptive 
signals are modulated by endogenous and exogenous agents which act on opioid, alpha 
adrenoceptors, GABA and glycine receptors (Leon-Casasola, 2007) 
 
Noxious stimuli not only result in tissue damage but also the release of intracellular 
contents from damage cells and inflammatory cells which leads to inflammation. 
Neurogenic inflammatory response also takes place and causes the release of substance P, 
neurokinin A and calcitonin gene-related peptides from the nociceptive afferent fibers. 
These peptides then change the excitability of sensory and sympathetic nerve fibers and 
lead to vasodilatation and release of chemical mediators from inflammatory cells. This 
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causes peripheral sensitization and increased responsiveness to mechanical and thermal 
stimuli (Latremoliere and woolf, 2009).    
  
In neural injury or inflammation, there will be an increment to the membrane excitability 
and synaptic efficacy of the nociceptive pathways and leads to central sensitization. The 
effect of central sensitization is to recruit previously subthreshold synaptic inputs to 
nociceptive neurons and generating an increased or augmented action potential output. 
Central sensitization is responsible to the changes in pain sensibility in acute and chronic 
clinical pain settings (Latremoliere and woolf, 2009).    
 
 
2.2  DEVELOPMENT OF CHRONIC POST SURGICAL PAIN 
 
A prolonged experience of acute pain in which long-standing changes are seen within and 
external to the central nervous system creates chronic pain with a histological and 
pathological basis (Ready and Laird, 1998). 
 
Neuroplasticity, or the physical remodelling of neuronal cytoarchitecture, occurs shortly 
after the onset of persistent acute pain and leads to the transition from acute pain into a 
chronic pain state. Due to peripheral lesion that persistently generates pain impulses to the 
spinal cord, inhibitory interneurones responsible for modulating painful nerve transmission 
impulses eventually die. In addition, glial cells remodel neuronal synapses to intensify 
nociceptive transmission. These pain-transmitting neurones become more sensitive, react 
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more intensely to stimuli, and grow more connections to second-order neurones within the 
CNS. This process leads to central sensitization in which activity dependent phenotypic 
changes are seen in the dorsal horn neurones and other CNS structures including higher 
centres (Torebjork, Lundberg and LaMotte, 1992).  Preceding long-term central 
sensitization, secondary hyperalgesia occurs within central nervous system and it is said to 
be responsible for chronic postsurgical pain (Eisenach, 2006). 
 
Figure 2.1 graphically summarizes the proposed mechanism of acute pain develops into 
chronic pain. The initial tissue injury which activates nociceptor then causes peripheral 
sensitization or primary hyperalgesia. While acute pain is usually modulated at the spinal 
cord level, prolonged and intense noxious transmission causes long lasting modifications 
to the central nervous system. This causes prolonged activation of C- fibers and followed 
by enhancement of NMDA receptor. This in turn leads to an up-regulation of cyclo-
oxygenase-2, nitric oxide synthetase and followed by increased prostaglandin synthesis 
and cannabinoid breakdown. As a result, neural and glial cells remodeling occurs and 
followed by long term potentiation of the nociceptive pathways. This in turn leads to 
development of chronic pain (Voscopoulos and Lema, 2010). 
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Figure 2.1. Peripheral and central roles of prostaglandin and cyclo-oxygenase-2 in pain 
perception and sensitization (Adopted from Voscopoulos and Lema, 2010) 
 
Most of the chronic pain syndrome is due to neuroplastic changes after injury, 
nevertheless, the exact mechanisms for the development of chronic post-surgical pain 
remain complex and poorly understood. Voscopoulos and Lema (2010) listed down 
chronic pain predisposing factors: 
a. Preoperative pain at the site of surgery or other body regions 
b. Psychosocial and mood factors 
c. Coping skills 
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d. Surgical factors 
• Nerve damage (complicated aetiology likely than just nerve injury alone) 
• Factors predisposing to prolonged inflammatory states (foreign materials) 
• Volume of surgeries performed per year for given operation 
• Recurrence of operation 
• Type of surgery 
• Length of surgery (lasting more than 3 hours) 
 
e. Genetic predisposition 
f. Acuity of postoperative pain 
g. Prolonged postoperative pain/inflammatory responses 
h. Duration of postoperative pain treatment 
i. Anaesthetic factors (general vs regional, type of general anaesthesia) 
j. Gender (female) 
k. Type of disease 
l. Recurrence of malignancy 
m. Adjuvant therapy: radiation, chemotherapy 
n. Age  
 
Among these factors, Perkins and Kehlet (2000) showed that the severity of postoperative 
pain is a strong predictor of subsequent chronic pain. 
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2.3  CONCEPTS IN PERI-OPERATIVE PAIN MANAGEMENT 
 
Peri-operative pain is an anticipated consequence of surgical procedure. More than 80% of 
patients who have undergone surgery complain of moderate to severe pain within the first 
few days after the procedure (Apfelbaum et al., 2003). In a survey, Filos et al. 1999 
reported that 50% of surgical patients say that they received inadequate pain relief after 
their operation. 
 
The concept of multimodal analgesia was introduced more than a decade ago as a 
technique to improve analgesia and reduce the incidence of opioid-related adverse events. 
The rationale for this strategy is to achieve sufficient analgesia with the additive or 
synergistic effects between different classes of analgesics. This allows for a reduction in 
the individual drugs dosage in addition to a lower incidence of adverse effects from any 
particular medication used for perioperative pain management. A lower incidence of 
adverse effects and improved analgesia has been demonstrated with multimodal analgesia 
techniques, which may provide for shorter hospitalization times, improved recovery and 
function (Buvanendran et al., 2003; White et al., 2007) and possibly decreased healthcare 
costs. Currently, the American Society of Anesthesiologists Task Force on Acute Pain 
Management advocates the use of multimodal analgesia (Ashburn et al., 2004). 
 
Figure 2.2 shows available modalities for the treatment of pain and site upon pain pathway 
at which these interventions act. Thus, an understanding of the mode and site of analgesic 
acts can help in better pain control for the patient. For instance, a patient going for total 
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knee replacement might receive epidural cocktail which consist of opioid and local 
anaesthetic in addition to oral NSAIDS, paracetamol and opioids in post-operative period. 
Recently, Elvir-Lazo and White (2010) summarized that improvements in patient outcome 
related to pain control can best be achieved by using a combination of analgesic technique 
involving both centrally and peripherally acting analgesic drugs.    
 
 
Figure 2.2. The pain pathway and interventions that can modulate activity at each point 
(Adapted from Ashburn et al., 2004) 
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As discussed earlier, severity of acute post-surgical pain predicts development of chronic 
post-surgical pain (Perkins and Kehlet, 2000). The pathophysiology of chronic pain 
development involves a cascade of sensitization involving the peripheral nervous system 
till central nervous system. In order to prevent this sensitization, the concept of preemptive 
analgesia was proposed. By preventing neuronal traffic in nociceptive fibers carrying pain 
signals to the central nervous system, it is possible to prevent central sensitization in ways 
that reduce both acute and chronic pain (Woolf and Chong, 1993). The main aims for 
preventive analgesia are to prevent spinal sensitization, reduce incidence of inflammatory 
or chronic pain and decrease pain after injury (Senturk, 2002). 
 
Instead of focusing on the treatment of physiological pain to noxious stimuli as practised in 
conventional perioperative analgesia regime, preemptive analgesia targets on the 
prevention or reversal of central and peripheral sensitization that may end up with 
hyperalgesia or pathological pain (Kissin, 2000). 
 
According to Kissin (2000), there are 3 different definitions used to define preemptive 
analgesia. These include treatment that (1) starts before surgery; (2) prevents establishment 
of central sensitization caused by incisional injury; and (3) prevent establishment of central 
sensitization caused by incisional and inflammatory injuries. Compared to conventional 
perioperative analgesia, preemptive analgesia is only centered on the prevention of 
pathological pain. 
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Preemptive analgesia uses drugs and local or regional anaesthesia. In keeping with 
pathophysiology of sensitization, analgesia should be given before noxious stimuli arise 
(Grape and Tramer, 2007). Nonetheless, the preemptive technique must also be 
multimodal, maintained and accompanied by active pain management during perioperative 
period. This is crucial for preemptive analgesia to be effective (Redmond et al., 2003).   
 
 
2.4 PATIENT CONTROLLED ANALGESIA 
 
Patient-controlled analgesia (PCA) is a delivery system in which patients self-administer 
predetermined doses of analgesic medication to relieve their pain. Since its introduction in 
the early 1980s, the daily management of postoperative pain has been extensively 
optimised. Morphine is the most studied and most commonly used intravenous drug for 
PCA (Grass 2005). In spite of the fact that it is the 'first choice' for PCA, other opioids 
have been successfully used for this option. These include diamorphine, meperidine, 
fentanyl and tramadol. However, there is no evidence from clinical studies that any 
particular opioid is more effective or associated with lower incidence of opioid side effects 
(Grass 2005). 
 
The pharmacokinetic basis of PCA is that patients titrate their plasma opioid 
concentrations to values above the minimum effective analgesic concentration (MEAC) 
but below the minimum toxic concentration (MTC), the so-called analgesic window. 
Although this is a useful concept to explain PCA, it is important to remember that the log 
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dose– response curve for opioid analgesia is not linear but a steep sigmoidal curve. This 
means that, once the analgesic threshold is reached, small increases in plasma 
concentration may result in effective analgesia. Further increases may lead to opioid side-
effects rather than further improvements in analgesia. In some patients (e.g. elderly, obese 
patients undergoing upper abdominal surgery), the difference between MEAC and MTC 
may be so small that it will be very difficult to provide analgesia without significant opioid 
side-effects, including respiratory depression (MacIntyre, 2001). 
 
PCA devices have been developed and evolved enormously in technological 
sophistication, ease of use, flexibility and portability (Grass, 2005). PCA is now routinely 
used in post-operative care throughout much of the developed world (Warfield and Kahn, 
1995; Carr, Miaskowski et al., 1998). PCA devices are programmable by the healthcare 
provider to deliver a specific amount of medication upon each request by the patient. A 
continuous ‘background’ infusion may or may not be co-administered in addition to patient 
controlled bolus doses. Bolus doses are limited by programmed ‘lockout interval’ within 
which subsequent requests are ignored or a cumulative limit to drug dose permitted in a 
fixed interval, such as one or four hours (Carr, Miaskowski et al., 1998). 
 
The use of PCA in hospitals has been increasing because of its proven advantages over 
conventional intramuscular injections which is round the clock analgesia prescription . 
These include improved pain relief, greater patient satisfaction, less sedation and fewer 
postoperative complications. Patients using PCA obtain better pain relief than those using 
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conventional analgesia, without an increase in side effects and no difference in duration of 
hospital stay (Ballantyne, Carr et al., 1993; Hudcova, McNicol et al., 2006).    
 
Nevertheless, there are incidences of equipment-related PCA complications, operator-
related or drug-related problems, device design and malfunctions being reported. The 
improvement on technology and staff training has greatly overcome these complications 
with equipment related PCA complications being less common than operator related 
complications (MacIntyre, 2001). With the introduction of an Acute Pain Service, 
management of postoperative pain by using PCA can be improved. 
 
In summary, PCA is a safe and popular method for postoperative pain control (Tuncer, 
Tosun et al., 2002). 
 
 
2.5.  PAIN ASSESSMENT TOOLS 
 
Pain, like many phenomena within human sensory experience, cannot be measured by 
external means and a patient report must be used. Pain measurement scales exploit aspects 
of the patient report that can yield reproducible data relating to the severity of the patient’s 
pain and the effects of treatment. A clinically useful pain scale must be easy for both 
patients and healthcare professionals to use and interpret whilst maintaining validity across 
a variety of disease states and cultures (Jensen et. al., 1992; Matthews et. al.,1990)].  
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In 2008, the Malaysian Ministry of Health implemented “Pain as the 5th Vital Sign” in 
hospitals across the country. Making pain a vital sign ensures the measuring and 
documenting of pain scores in all patients.  
 
By objectively gauging pain using various pain-scoring systems, the difficulties in 
quantifying pain intensity and the problem of inter-observer perception can be overcome. 
Most scales make pain measurable, and can tell providers if the pain is mild, moderate or 
severe. The investigator can also follow the trend of the patient’s pain making it easier to 
find appropriate treatment (Huskisson, 1974).  
 
 The pain assessment scales are either unidimensional or multidimensional scales.  
 
2.5.1 UNIDIMENSIONAL SCALE 
Unidimensional scales are easy to use and provide quick feedback on the effectiveness of 
the intervention made. These scales assess a single dimension of pain and measures pain 
intensity through self-reporting measures; 
a. Numerical Rating Scale (NRS)  
b. Visual Analog Scale (VAS)  
c. Verbal Rating Scale (VRS) 
 
 
20 
 
2.5.1.1   NUMERICAL RATING SCALE (NRS) 
 
Numerical rating scales (NRS) take the two extremes of the pain experience (for example, 
‘no pain’ and ‘worst pain imaginable’) and assign numbers to levels of pain in between. It 
is assumed that each number represents a proportional increase in the pain severity. NRS 
are robust and reproducible pain scales. They are simple for patients to understand and 
there is evidence that the elderly find them easier to use than visual analogue scores. 
Recording data from the scores is also straightforward as numbers can simply be read off 
the marked scales (Jensen et. al., 1992; Matthews et. al.,1990).   
 
 
Figure 2.3.   Numeric Rating Scale     (Adapted from Jensen et. al., 1992)  
 
 
2.5.1.2   VISUAL ANALOG SCALE (VAS) 
 
A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a 
characteristic or attitude which is presumed to range across continuous values and cannot 
be easily measured directly. VAS is usually presented as a horizontal line, 10 cm in length, 
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explained by word descriptors at each end (as shown below). The patient marks at the 
point on the line that they feel represent their perception of current state of pain (Wong 
DL, Perry SE, Hockenberry MJ et al. 2002). 
 
 
 
Figure 2.4.   Visual Analog Scale  (Adapted from Wong DL et. al. 2002) 
 
 
2.5.1.3   VERBAL RATING SCALE (VRS) 
 
Verbal rating scales (VRS) aim to stratify pain intensity according to levels of severity 
represented by commonly used adjectives. Such scales may be simple and consist of as few 
as 3 levels, associated with adjectives such as ‘mild’, ‘moderate’ and ‘severe’. More levels 
can be used, but problems tend to arise due to inter-patient differences in the interpretation 
of the adjectives used. VRS are widely applied and there is no doubt that a 3 or 4 level 
scale is the easiest for patients to use (Jensen et. al., 1992; Matthews et. al.,1990).   
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2.5.2 MULTIDIMENTIONAL SCALE 
Multidimensional scales measures intensity, nature and location of pain as well as the 
impact pain is having on patient activity and mood. These scales are useful for patients 
with persistent acute or chronic pain. 
a. Brief Pain Inventory (BPI) 
b. McGill Pain Questionnaire (MPQ) 
c. Memorial Pain Assessment Card  
 
The Wong-Baker Faces Scale and the FLACC (Faces, Legs, Activity, Cry, Consolability) 
scale is used in children or patients with cognitive impairment.  
 
 Pain in infants is assessed using the CRIES scale. This scale uses 5 variables. Crying, 
Requirement of oxygen, Increased vital signs, Expression and Sleeplessness to assess 
postoperative pain (van Dijk et al., 2000). 
 
In this study, Numerical Rating Scale was chosen mainly due to the author preference. 
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2.6  PREGABALIN 
 
2.6.1 INTRODUCTION 
 
 
 
Figure 2.5. Structure of Pregabalin 
 
Pregabalin (S-[+]-3 isobutylgaba) was designed as a lipophilic GABA (γ-aminobutyric 
acid) analogue substituted at the ‘3’ position to facilitate diffusion across the blood-brain 
barrier. It has structural analogue of the inhibitory neurotransmitter g-aminobutyric acid, 
but it is not functionally related to it (Ben-Menachem, 2004). Pregabalin is the 
pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid, and has 
a similar pharmacological profile to gabapentin (Frampton and Foster, 2005). Though the 
precise mode of action of pregabalin has not been fully elucidated, it does interact with the 
same binding site and like its predecessor, gabapentin, it binds to the α-2-δ subunit of 
voltage-gated calcium channels, reducing the release of several excitatory 
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neurotransmitters and blocking the development of hyperalgesia and central sensitization 
(Snheker et al, 2005; Chizh et al., 2007).  
 
Pregabalin appears to produce an inhibitory modulation of neuronal excitability, 
particularly in areas such as the neocortex, amygdala, and hippocampus. Pregabalin has 
anticonvulsant, anti-hyperalgesic, and anxiolytic properties similar to gabapentin but 
several times more potent than gabapentin while producing fewer adverse effects (Ben-
Menacham, 2004). 
 
2.6.2 ANTINOCICEPTIVE MECHANISM OF ACTION 
 
The exact mechanism of how Pregabalin works is still unknown. Although it is an 
analogue of gamma-aminobutyric acid (GABA), it is neither active at GABAA or GABAB 
receptors nor metabolically converted to GABA (Piechan et al., 2004). Nevertheless, in 
cultured neurons, prolonged application of pregabalin increases the density of GABA 
transporter protein and increases the rate of functional GABA transport. Pregabalin does 
not block sodium channels, is not an opiate receptors agonist and does not alter cyclo-
oxygenase enzyme activity. It is also inactive at serotonin and dopamine receptors (Piechan 
et al., 2004). 
 
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-
gated calcium channels) in central nervous system tissues. Results with genetically 
modified mice and with compounds structurally related to pregabalin (such as gabapentin) 
